Ocugen, Inc.OCGNEarnings & Financial Report
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, including rare inherited retinal disorders and age-related eye conditions. It operates primarily in the North American market, with a pipeline covering gene therapies, biologics, and vaccine candidates targeting unmet medical needs.
Revenue
$1.4M
Gross Profit
N/A
Operating Profit
$-13.8M
Net Profit
$-14.7M
Gross Margin
N/A
Operating Margin
-1004.7%
Net Margin
-1073.5%
YoY Growth
20.3%
Ocugen, Inc. Q2 FY2025 Financial Summary
Ocugen, Inc. reported revenue of $1.4M (up 20.3% YoY) for Q2 FY2025, with a net profit of $-14.7M (up 3.5% YoY) (-1073.5% margin).
Key Financial Metrics
| Total Revenue | $1.4M |
|---|---|
| Net Profit | $-14.7M |
| Gross Margin | N/A |
| Operating Margin | -1004.7% |
| Report Period | Q2 FY2025 |
Ocugen, Inc. Annual Revenue by Year
Ocugen, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.4M |
| 2024 | $4.1M |
| 2023 | $6.0M |
| 2022 | $2.5M |
Ocugen, Inc. Quarterly Revenue & Net Profit History
Ocugen, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $-193.0K | -125.3% | N/A | N/A |
| Q3 FY2025 | $1.8M | +54.2% | $-20.1M | -1144.5% |
| Q2 FY2025 | $1.4M | +20.3% | $-14.7M | -1073.5% |
| Q1 FY2025 | $1.5M | +46.1% | $-15.3M | -1036.5% |
| Q4 FY2024 | $764.0K | -45.8% | N/A | N/A |
| Q3 FY2024 | $1.1M | -69.3% | $-13.0M | -1141.7% |
| Q2 FY2024 | $1.1M | +135.3% | $-15.3M | -1339.2% |
| Q1 FY2024 | $1.0M | +128.9% | $-11.9M | -1175.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.1M | $1.1M | $764000 | $1.5M | $1.4M | $1.8M | $-193000 |
| YoY Growth | 128.9% | 135.3% | -69.3% | -45.8% | 46.1% | 20.3% | 54.2% | -125.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $51.8M | $40.5M | $61.9M | $82.4M | $64.5M | $53.6M | $57.6M | $43.5M |
| Liabilities | $21.5M | $23.6M | $21.3M | $52.8M | $48.5M | $50.5M | $54.1M | $55.7M |
| Equity | $30.3M | $16.9M | $40.6M | $29.6M | $15.9M | $3.1M | $3.5M | $-12.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.6M | $-9.9M | $-11.3M | $-10.4M | $-19.4M | $-10.7M | $-12.9M | $-14.0M |